TCT 2018 | ULTIMATE: IVUS Guided DES Implantation for All Vessels, for All Lesions

Intravascular Ultrasound (IVUS) guided drug eluting stent (DES) implantation is associated with less adverse events compared against angiography guided stenting. This is especially clear for certain populations (with left main PCI as paradigmatic) but not so clear when dealing with all comers.

TCT 2018 | ULTIMATE: Implante de DES guiado por IVUS, para todos los vasos, para todas las lesiones1448 all comer patients requiring DES stenting were randomized 1:1 to IVUS guided vs. angiography guided procedures.  Primary end point at 12 months was a composite of cardiac death, target vessel myocardial infarction or clinically driven target vessel revascularization. The procedure was considered successful if all IVUS optimal implantation criteria were met.

 

At 12 months, there was 2.9% events rate in the IVUS group vs 5.4% in the angiography guided group (p=0.019). These events happen in only 1.6% of patients who complied with optimal implantation criteria by IVUS. If one criterion was not met, the figure would rise to 4.4% (p=0.029).


Read also: TCT 2018 | SYNTAXES: 10 Year Follow Up is ‘Trendy’.


There was also significant reduction of target vessel revascularization and definite thrombosis.

 

IVUS was shown to reduce events in an unselected population of patients, and not only in complex PCI.

 

Original title: Intravascular Ultrasound-Guided Versus Angiography-Guided Implantation of Drug- Eluting Stent in All-Comers: The ULTIMATE trial.

Presenter: Junjie Zhang.

 

ULTIMATE-presentación

ULTIMATE-artículo-original


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 – ECLIPSE: Randomized Study of Orbital Atherectomy vs Conventional PCI in Severely Calcified Lesions

Coronary calcification is associated with stent under-expansion and increased risk of both early and late adverse events. Atherectomy is an essential tool for uncrossable...

TCT 2024 | Use of Drug-Coated Balloons for Side Branch Treatment in Provisional Stenting

In some cases, treating coronary bifurcations with provisional stenting requires side branch stenting, which may lead to suboptimal outcomes. Drug-coated balloons (DCBs) have emerged...

TCT 2024 | Use of Artificial Intelligence for Patients with Suspected Coronary Artery Disease

The current approach to chest pain mainly focuses on symptom characteristics, conducting functional tests for ischemia assessment. However, several randomized clinical trials have shown...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 | TRISCEND II

This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...